{
    "info": {
        "nct_id": "NCT04837677",
        "official_title": "A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors",
        "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)\n* Left ventricular ejection fraction of ≥ 50%\n* Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial\n* Patients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity ≤ Grade 1)\n* All patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 28 days, whichever is longer before study entry\n* Most recent lab values meet the following criteria:\n\n  * Absolute neutrophil count > 1.0 x 10^3/μL;\n  * Platelet count > 75,000/μL;\n  * Hemoglobin > 9.0 g/dL\n* Histologically confirmed advanced or metastatic solid tumor indicated below that is relapsed, refractory, or intolerant to available therapies with known benefit:\n\n  * Sarcoma not amendable to curative treatment with surgery or radiotherapy;\n  * Melanoma (non-resectable or metastatic);\n  * Small cell lung cancer (extensive-stage);\n  * Non-small cell lung cancer;\n  * Triple negative breast cancer (histopathologically or cytologically confirmed).\n  * Esophageal cancer\n  * Cervical cancer\n  * Head and neck cancer\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known hypersensitivity to any of the components of PRT1419\n* Primary malignancies of the CNS, or uncontrolled CNS metastases, including impending spinal cord compression\n* Female patients who are pregnant or lactating\n* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption\n* Mean QTcF interval of >480 msec\n* History of heart failure, additional risk factors for arrhythmias or requiring concomitant medications that prolong the QT/QTc interval\n* HIV positive; known active hepatitis B or C\n* Uncontrolled intercurrent illnesses\n* Treatment with strong inhibitors of CYP2C8\n* Prior exposure to an MCL1 inhibitor\n* History of another malignancy except:\n\n  * Malignancy treated with curative intent with no known active disease for >2 years at study entry;\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;\n  * Adequately treated carcinoma in situ without evidence of disease;\n  * Other concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Head and neck cancer",
            "criterions": [
                {
                    "exact_snippets": "Head and neck cancer",
                    "criterion": "head and neck cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function (bone marrow, hepatic, renal, cardiovascular)",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ function (bone marrow, hepatic, renal, cardiovascular)",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ function (bone marrow, hepatic, renal, cardiovascular)",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ function (bone marrow, hepatic, renal, cardiovascular)",
                    "criterion": "cardiovascular function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Esophageal cancer",
            "criterions": [
                {
                    "exact_snippets": "Esophageal cancer",
                    "criterion": "esophageal cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed advanced or metastatic solid tumor indicated below that is relapsed, refractory, or intolerant to available therapies with known benefit:",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed advanced or metastatic solid tumor indicated below",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed, refractory, or intolerant to available therapies with known benefit",
                    "criterion": "response to available therapies with known benefit",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "relapsed",
                                "refractory",
                                "intolerant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test within 7 days of the start of treatment",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days of the start of treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use a highly effective method of contraception during the trial",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the trial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction of ≥ 50%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction of ≥ 50%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Triple negative breast cancer (histopathologically or cytologically confirmed).",
            "criterions": [
                {
                    "exact_snippets": "Triple negative breast cancer",
                    "criterion": "breast cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "triple negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "histopathologically or cytologically confirmed",
                    "criterion": "breast cancer diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histopathology",
                                "cytology"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count > 75,000/μL;",
            "criterions": [
                {
                    "exact_snippets": "Platelet count > 75,000/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 75000,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Most recent lab values meet the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Most recent lab values",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "most recent"
                        },
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sarcoma not amendable to curative treatment with surgery or radiotherapy;",
            "criterions": [
                {
                    "exact_snippets": "Sarcoma not amendable to curative treatment with surgery or radiotherapy",
                    "criterion": "sarcoma",
                    "requirements": [
                        {
                            "requirement_type": "amenability to curative treatment with surgery or radiotherapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-small cell lung cancer;",
            "criterions": [
                {
                    "exact_snippets": "Non-small cell lung cancer",
                    "criterion": "non-small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count > 1.0 x 10^3/μL;",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count > 1.0 x 10^3/μL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1000,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 28 days, whichever is longer before study entry",
            "criterions": [
                {
                    "exact_snippets": "All patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 28 days, whichever is longer before study entry",
                    "criterion": "washout period after prior investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "duration since last investigational agent",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cervical cancer",
            "criterions": [
                {
                    "exact_snippets": "Cervical cancer",
                    "criterion": "cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Melanoma (non-resectable or metastatic);",
            "criterions": [
                {
                    "exact_snippets": "Melanoma (non-resectable or metastatic)",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease_stage",
                            "expected_value": [
                                "non-resectable",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Small cell lung cancer (extensive-stage);",
            "criterions": [
                {
                    "exact_snippets": "Small cell lung cancer (extensive-stage)",
                    "criterion": "small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "extensive-stage"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity ≤ Grade 1)",
            "criterions": [
                {
                    "exact_snippets": "Patients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity ≤ Grade 1)",
                    "criterion": "recovery from prior therapy toxicity",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Uncontrolled intercurrent illnesses",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illnesses",
                    "criterion": "intercurrent illnesses",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another malignancy except:",
            "criterions": [
                {
                    "exact_snippets": "History of another malignancy",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any of the components of PRT1419",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any of the components of PRT1419",
                    "criterion": "hypersensitivity to components of PRT1419",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with strong inhibitors of CYP2C8",
            "criterions": [
                {
                    "exact_snippets": "Treatment with strong inhibitors of CYP2C8",
                    "criterion": "treatment with strong inhibitors of CYP2C8",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor.",
            "criterions": [
                {
                    "exact_snippets": "Other concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor.",
                    "criterion": "concurrent low-grade malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "malignancy grade",
                            "expected_value": "low-grade"
                        },
                        {
                            "requirement_type": "sponsor consultation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Primary malignancies of the CNS, or uncontrolled CNS metastases, including impending spinal cord compression",
            "criterions": [
                {
                    "exact_snippets": "Primary malignancies of the CNS",
                    "criterion": "primary CNS malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "impending spinal cord compression",
                    "criterion": "impending spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancy treated with curative intent with no known active disease for >2 years at study entry;",
            "criterions": [
                {
                    "exact_snippets": "Malignancy treated with curative intent",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "no known active disease for >2 years at study entry",
                    "criterion": "active disease",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration_of_absence",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of heart failure, additional risk factors for arrhythmias or requiring concomitant medications that prolong the QT/QTc interval",
            "criterions": [
                {
                    "exact_snippets": "History of heart failure",
                    "criterion": "heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "additional risk factors for arrhythmias",
                    "criterion": "risk factors for arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring concomitant medications that prolong the QT/QTc interval",
                    "criterion": "concomitant medications that prolong the QT/QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption",
            "criterions": [
                {
                    "exact_snippets": "Inflammatory disorders of the gastrointestinal tract",
                    "criterion": "inflammatory disorders of the gastrointestinal tract",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with GI malabsorption",
                    "criterion": "GI malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who are pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Female patients who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female patients who are ... lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Mean QTcF interval of >480 msec",
            "criterions": [
                {
                    "exact_snippets": "Mean QTcF interval of >480 msec",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "mean value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated carcinoma in situ without evidence of disease;",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated carcinoma in situ without evidence of disease",
                    "criterion": "carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        },
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "lentigo maligna without evidence of disease",
                    "criterion": "lentigo maligna",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "without evidence of disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to an MCL1 inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to an MCL1 inhibitor",
                    "criterion": "MCL1 inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* HIV positive; known active hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "HIV positive",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis B",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}